Treatment of cells with GZ17-6.02, [trametinib + dabrafenib] or the agents in combination enhanced the expression of MHCA and decreased the levels of PD-L1, which would predict for a greater anti-tumor immunotherapy response in vivo (Figure 11A). Here, CD274 is linked to neoplasm.